密切关注冠科生物团队的最新构想和新闻动态。

  • racing-resize-638x300

    CAR T IMMUNOTHERAPY REVS UP FOR GLIOBLASTOMA

    A NEW CLINICAL TRIAL IN GLIOBLASTOMA HAS BEEN LAUNCHED BASED ON AN INNOVATIVE IMMUNOTHERAPEUTIC TECHNIQUE – THE CAR T CELL WHICH CAN MODIFY THEN HARNESS A PATIENT’S OWN T CELLS TO FIGHT THEIR DISEASE. Immunotherapy news (including our blog) often focusses on checkpoint inhibitors likeanti-PD-1 and anti-CTLA-4 antibodies, as they make important leaps forward in… Read more »

  • metamorphosis-resize-638x300

    PRECISION PROFILING USING PDX MODELS: THE EASY WAY TO TRANSFORM YOUR DRUG DISCOVERY PROGRAM

    IMPROVED PRECLINICAL MODELS ARE NEEDED IN ONCOLOGY DRUG DEVELOPMENT TO REDUCE THE HIGH FAILURE RATE OF NEW AGENTS. PRECISION PROFILING TRANSLATIONAL PLATFORMS ARE PROVIDING THESE TOOLS, USING PATIENT-DERIVED XENOGRAFT MODELS TO REFLECT THE DIVERSITY OF THE HUMAN CANCER PATIENT POPULATION. CROWN BIOSCIENCE ARE CURRENTLY EXPANDING OUR DIVERSITY AND PDX COLLECTION THROUGH THE EXCITING ACQUISITION OF… Read more »

  • breakthrough-face-resize-638x300

    BLADDER CANCER BREAKTHROUGH FOR IMMUNOTHERAP

    NEW TREATMENTS FOR BLADDER CANCER HAVE BEEN EXTREMELY SCARCE OVER THE PAST DECADES. HOWEVER, THE CONTINUED RISE OF CHECKPOINT INHIBITOR IMMUNOTHERAPIES MAY BE PROVIDING A NEW BREAKTHROUGH FOR METASTATIC DISEASE. NEW DEVELOPMENTS IN THE NEXT GENERATION OF IMMUNO-ONCOLOGY MODELS ARE ALSO UP AND COMING THANKS TO AN EXTENDED ALLIANCE BETWEEN CROWN BIOSCIENCE AND THE NATIONAL… Read more »

  • iStock_000042756696Medium-638x300

    A KNOCKOUT JAB FOR BREAST CANCER?

    IMMUNOTHERAPY CONTINUES TO BE A HOT TOPIC IN ONCOLOGY RESEARCH THIS YEAR, WITH BREAST CANCER VACCINES SHOWING PROMISE IN EARLY PHASE CLINICAL STUDIES. RECENTLY PUBLISHED RESEARCH HAS SHOWN THAT A VACCINE TARGETING MAMMAGLOBIN-A (WHICH IS EXPRESSED IN THE MAJORITY OF BREAST CANCERS) IS NOT ONLY WELL-TOLERATED, BUT ALSO SHOWS SURPRISINGLY GOOD EFFICACY IN A PHASE… Read more »

  • twin-resize-1-638x300

    A DOUBLE TAKE ON DIABETES RESEARCH

    IDENTICAL TWINS SHARE THE SAME GENETIC MAKE-UP, YET DUE TO LIFESTYLE CHOICES NOT ALWAYS THE SAME DEVELOPMENT OF CHRONIC DISEASES SUCH AS TYPE 2 DIABETES (T2D). RESEARCHERS HAVE INVESTIGATED THE MOLECULAR MECHANISMS THAT INDUCE T2D VIA AN IDENTICAL TWIN STUDY, WITH THE AIM TO BETTER UNDERSTAND WHY ONE TWIN DEVELOPS THE DISEASE WHILE THE OTHER… Read more »

  • race-flame-resize-638x300

    THE LUNG CANCER IMMUNOTHERAPY RACE HEATS UP!

    IMMUNOTHERAPY AS AN ONCOLOGY TREATMENT PARADIGM REALLY CAME OF AGE IN 2014, WITH THE FIRST FDA APPROVALS OF ANTI-PD-1/PD-L1 THERAPIES IN ADVANCED MELANOMA. DEVELOPMENTS IN THE FIELD LOOK LIKE THEY ARE NOT SLOWING DOWN IN 2015, WITH THE RACE ON FOR APPROVAL IN THE MUCH LARGER LUNG CANCER PATIENT POPULATION. Targeting cancer by taking advantage… Read more »

  • high-jump-resize-638x300

    FDA DRUG APPROVALS REACH NEW HEIGHTS

    THE US FDA APPROVED 41 NOVEL NEW MEDICINES IN 2014, THE HIGHEST NUMBER OF APPROVALS FOR 18 YEARS. THE LIST COVERED A WIDE VARIETY OF DISEASE INDICATIONS AND INCLUDED BOTH INTERESTING ANTICANCER AND ANTIDIABETIC AGENTS, AND NOTABLY 15 ORPHAN DRUGS. WE REVIEW THE BIG HITTERS THAT MADE THE LIST, AND WHY SOME PRICEY AGENTS ARE… Read more »

  • darwin3-638x300

    CANCER EVOLUTION: NATURALLY SELECTING DRUG RESISTANCE?

    DARWIN’S THEORY OF NATURAL SELECTION WAS PUBLISHED IN 1859, EXPLAINING HOW NATURE SELECTS CERTAIN ADVANTAGEOUS PHYSICAL ATTRIBUTES (OR PHENOTYPES) TO PASS ON TO THEIR OFFSPRING, SO THAT THEY CAN BETTER SURVIVE IN THEIR ENVIRONMENT. NOW OVER 150 YEARS LATER, THE THEORY IS BECOMING A TALKING POINT IN ONCOLOGY, WITH NATURAL SELECTION WITHIN TUMORS HELPING TO… Read more »

  • Grading-resize-638x300

    NIVOLUMAB AND CARFILZOMIB GET TOP MARKS AT ASH 2014

    CROWN BIOSCIENCE ENJOYED AN INTERESTING CONFERENCE AT THE 56TH ASH ANNUAL MEETING IN SAN FRANCISCO LAST WEEK. AS WELL AS CATCHING UP WITH RESEARCHERS AND CLINICIANS TO DISCUSS OUR NEW MODELS AND DATA, WE ALSO REVIEWED THE REST OF THE CONFERENCE TO BRING YOU THE HOT HEMATOLOGY TOPICS OF THE MEETING. TOP STORIES INCLUDED THE… Read more »

  • joggins-resize2-638x300
  • baking-resize-2-638x300

    COMBINATION THERAPIES MIX THINGS UP AT EORTC

    CROWN BIOSCIENCE RECENTLY ATTENDED THE 26TH EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS IN BARCELONA. AS WELL AS MANNING A POPULAR BOOTH AND PRESENTING FOUR SCIENTIFIC POSTERS, WE ALSO REVIEWED THE BEST OF THE DRUG DEVELOPMENT RESEARCH ON DISPLAY. A PARTICULARLY HOT TOPIC AT THIS YEAR’S CONFERENCE WAS COMBINATION THERAPIES. Combination therapies are extremely… Read more »

  • iStock_000006984923Mediumresize-638x300

    FINDING THE BEST TREATMENT FOR OVARIAN CANCER

    THE EARLY DETECTION AND CORRECT DIAGNOSIS OF CANCER IS IMPORTANT TO OPTIMIZE TREATMENT REGIMENS, AND TO GIVE PATIENTS THE BEST CHANCE OF RESPONSE AND SURVIVAL. DIAGNOSIS OF OVARIAN CANCER IS OFTEN DIFFICULT, AS IS CORRECTLY STAGING THE DISEASE, WHICH CAN LEAD TO PATIENTS NOT RECEIVING THE BEST TREATMENT FOR THEIR CANCER TYPE. A NEW TEST… Read more »

  • doorknocker-resize2

    OPPORTUNITY KNOCKS FOR ONCOLOGY CLINICAL TRIALS

    PATIENT PARTICIPATION IN ONCOLOGY CLINICAL TRIALS IS VERY LOW DUE TO PATIENT CONCERNS INCLUDING WORRIES OVER EXPERIMENTAL DRUG EFFECTIVENESS AND UNCERTAINTY AROUND JOINING CLINICAL TRIALS VERSUS USING A STANDARD THERAPY. NEW METHODS ARE NEEDED TO ENCOURAGE HIGHER ENROLMENT, ONE OF WHICH IS ‘WINDOW OF OPPORTUNITY TRIALS’ WHICH USE GAPS IN EARLY STANDARD OF CARE TREATMENT… Read more »

  • seesaw-resized

    THE UPS AND DOWNS OF AN ANGIOGENESIS INHIBITOR

    TARGETED THERAPIES CAN OFTEN BE USED IN MULTIPLE DIFFERENT CANCER TYPES, DEPENDENT ON MULTIPLE CANCERS ALL HAVING THE SAME TARGET, SUCH AS AN UPREGULATED OR OVEREXPRESSED PROTEIN, OR ALL HAVING THE SAME MUTATION. ONE EXAMPLE OF THIS IS VEGF AND VEGF RECEPTOR (VEGFR) INHIBITORS, WHICH ACT AS ANTIANGIOGENIC AGENTS AND BLOCK THE FORMATION OF NEW… Read more »

  • iStock_000020973507Mediumresize

    STEM CELLS – THE FIRST STEP TOWARDS A CURE FOR TYPE 1 DIABETES?

    TYPE 1 DIABETES HAS RECENTLY BEEN THE FOCUS OF FORWARD THINKING RESEARCH, EMBRACING TECHNOLOGICAL AND SCIENTIFIC ADVANCES TO FIND NEW AND INNOVATIVE TREATMENT OPTIONS. NOW, STEM CELL RESEARCH HAS TAKEN THE FIRST STEPS TOWARD FINDING A POTENTIAL CURE FOR THIS CHRONIC AND LIFE-ALTERING DISEASE. Type 1 is often the overlooked form of diabetes as it… Read more »

  • Child looking through binoculars

    SPOTTING THE EARLY SIGNS OF PANCREATIC CANCER

    PANCREATIC CANCER IS USUALLY DIAGNOSED AT A LATE STAGE, WHICH HAS RESULTED IN THE DISEASE HAVING PARTICULARLY POOR SURVIVAL RATES AROUND THE WORLD. FINDING METHODS TO ALLOW EARLIER DETECTION AND TREATMENT COULD MASSIVELY IMPROVE PATIENT SURVIVAL, AND ARE A HOT RESEARCH TOPIC IN THE FIELD. A RECENT STUDY INVESTIGATING ALTERED METABOLISM IN PANCREATIC ADENOCARCINOMA PATIENTS… Read more »

  • black targets and arrow sky

    LEUKEMIA: A NEW TARGET FOR PARP INHIBITORS?

    MANY AGENTS IN CANCER RESEARCH TARGET SPECIFIC MOLECULES OR PATHWAYS, MEANING THEY ARE ONLY EFFECTIVE IN A CERTAIN SUBSET OF PATIENTS. FINDING ANOTHER USE FOR AN ALREADY DEVELOPED DRUG CAN CUT DOWN ON EARLY STAGE RESEARCH AND OFFER NEW HOPE TO OTHER PATIENT GROUPS. THIS COULD BE HAPPENING SOON IN LEUKEMIA, WHERE PRECLINICAL RESEARCH HAS… Read more »

  • england-hand-resize2-638x300

    ONCOLOGY AGENTS NOT HAVING A NICE TIME IN ENGLAND

    POTENTIAL NEW ONCOLOGY AGENTS IN ENGLAND NEED TO BE APPROVED BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) BASED ON THEIR COST-EFFECTIVENESS. HOWEVER OVER THE PAST COUPLE OF YEARS AND MUCH TO THE DISAPPOINTMENT OF THE GENERAL PUBLIC, NICE HAVE REJECTED A STRING OF ONCOLOGY AGENTS, INCLUDING RECENTLY KADCYLA® FOR ADVANCED BREAST CANCER…. Read more »

  • mic-narrow

    ESSENTIAL ESMO: CRIZOTINIB TAKES CENTER STAGE

    LAST WEEK SAW THE CLOSE OF THE 2014 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS IN MADRID, THE THEME OF WHICH WAS ‘PRECISION MEDICINE IN CANCER CARE’. CROWN BIOSCIENCE HAVE REVIEWED THE BEST OF THE RESEARCH TO BE PRESENTED, AND WERE PARTICULARLY INTERESTED TO SEE CRIZOTINIB BACK IN THE SPOTLIGHT IN A POTENTIAL NEW NSCLC INDICATION…. Read more »

  • Medical touchscreen
  • iStock_000016113842Medium

    RESEARCHERS DIGEST UP STOMACH CANCER

    STOMACH CANCER IS THE THIRD BIGGEST CANCER KILLER WORLDWIDE, WITH NEW THERAPIES PROVING DIFFICULT TO DEVELOP DUE TO THE DIVERSITY OF THE DISEASE, AND A CLASSIFICATION SYSTEM WHICH HAS LIMITED CLINICAL USE. HOWEVER, NEWLY PUBLISHED RESEARCH HAS BROKEN DOWN STOMACH CANCER INTO 4 BITE SIZED PORTIONS, EACH WITH THEIR OWN DISTINGUISHING FEATURES, WITH THE HOPE… Read more »

  • roulette

    THE INCREASED ODDS OF DEVELOPING DIABETES

    DUE TO INCREASING OBESITY LEVELS, INACTIVITY, AND AN AGING POPULATION WORLDWIDE THE PREVALENCE OF TYPE 2 DIABETES HAS REACHED EPIDEMIC PROPORTIONS. THE WORLD HEALTH ORGANIZATION REPORTS THAT 347 MILLION PEOPLE GLOBALLY HAVE DIABETES, WITH TYPE 2 ACCOUNTING FOR 90% OF CASES. WHILST TYPE 2 DIABETES PREVALENCE RATES HAVE BEEN INCREASING IN THE US RECENTLY, (FROM… Read more »

  • iStock_000026471675Medium-638x300

    MERCK FIRST PAST THE US POST IN ANTI-PD-1 THERAPIES

    IMMUNOTHERAPY IS AT THE FOREFRONT OF ONCOLOGY RESEARCH, WITH MANY COMPANIES FOCUSING ON THE SAME SPECIFIC TARGETS IN MULTIPLE CANCER TYPES. THE RACE HAS BEEN ON FOR THE FIRST US APPROVAL OF AN ANTI-PD-1 AGENT, AND MERCK HAVE PROVED VICTORIOUS WITH THE FDA SAYING YES TO KEYTRUDA (PEMBROLIZUMAB) IN ADVANCED MELANOMA JUST LAST WEEK. Anti… Read more »

  • jumpingnarrow-638x300

    激活胶质母细胞瘤的免疫系统

    过去,肿瘤的放射治疗是基于放射线可以杀死细胞并且可以选择性地针对肿瘤组织发挥作用。最近出现了一种新的治疗模式,即将放射疗法与目前火热的免疫疗法相结合来探索其带来的治疗优势以延长病人生存期。最近该领域的临床前研究表明,三联疗法(是指利用局部病灶放射治疗和两种免疫治疗剂相结合来促进治疗效果)显著提高了恶性胶质瘤患者的生存期…

  • squarepeg-round-hole-cropped-638x300

    FIND THE RIGHT WAY TO USE PDX IN PERSONALIZED MEDICINE RESEARCH

    PERSONALIZED MEDICINE IS THE FUTURE OF CANCER THERAPY, AND MANY TECHNIQUES ARE BEING USED TO DRIVE FORWARD RESEARCH IN THIS AREA. PATIENT-DERIVED XENOGRAFT (PDX) MODELS ARE AT THE FOREFRONT OF PERSONALIZED MEDICINE RESEARCH IN HUMAN SURROGATE TRIALS, BUT OTHER APPROACHES TO USING PDX ARE ALSO BEING PIONEERED WHICH MAY NOT BRING THE FULL PATIENT BENEFIT… Read more »

  • iStock_000015336775Medium-600x300

    AN OLD NEED FOR NEW THERAPIES IN CLL

    CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS A CANCER TYPE MAINLY SEEN IN ELDERLY PEOPLE, WITH THE AVERAGE AGE OF DIAGNOSIS BEING 72 YEARS OLD. HOWEVER, ELDERLY PATIENTS HAVE BEEN UNDERREPRESENTED IN CLL CLINICAL TRIALS, AND THE CURRENT GOLD STANDARD TREATMENT OF CHEMOIMMUNOTHERAPY IS ONLY VIABLE FOR PHYSICALLY FIT PEOPLE UNDER 65, WHICH RULES OUT THE MAJORITY… Read more »

  • iStock_000020334121Medium-638x300

    FINDING THE RIGHT PATH IN LUNG CANCER THERAPY

    LUNG CANCER IS THE BIGGEST CANCER KILLER WORLDWIDE, WITH HISTORICALLY LOW SURVIVAL RATES AND A HIGH NUMBER OF CASES CAUSED BY SMOKING. WITH TARGETED THERAPIES NOW GREATLY IMPROVING TREATMENT OPTIONS, RESEARCH IS NEEDED TO UNCOVER ALL OF THE MECHANISMS AND ONCOGENES WHICH ARE DRIVING LUNG CANCER FORWARD. NEWLY PUBLISHED RESEARCH HAS IDENTIFIED NOVEL MUTATIONS THAT… Read more »

  • iStock_000004719007Medium-600x300

    GUIDING THE WAY IN PRECLINICAL RADIATION RESEARCH

    RADIOTHERAPY IS A COMMON TREATMENT FOR MANY CANCER TYPES, AND IN RECENT YEARS HAS BECOME EXTREMELY EFFECTIVE USING IMAGE GUIDED TECHNIQUES. HOWEVER, PRECLINICAL IRRADIATION MODELS HAD FALLEN BEHIND, WITH A LACK OF METHODS THAT WERE COMPARABLE TO CLINICAL TREATMENTS. THE GAME CHANGING SMALL ANIMAL RADIATION RESEARCH PLATFORM (SARRP) FROM XSTRAHL HAS BEEN TURNING THIS AROUND,… Read more »

  • idea-neede-reszied-2-638x300

    FGF1 INJECTS FRESH IDEAS INTO TYPE 2 DIABETES RESEARCH

    TYPE 2 DIABETES CANNOT BE CURED AND IS MANAGED BY A REGIMEN OF EXERCISE, DIET, AND DRUGS. AS THE CURRENTLY AVAILABLE TREATMENTS HAVE A RAFT OF SIDE EFFECTS, INCLUDING WEIGHT GAIN AND BLOOD SUGAR DROPPING TO DANGEROUSLY LOW LEVELS, NEW THERAPIES ARE NEEDED TO CONTROL THE DISEASE WITH FEWER COMPLICATIONS. SOME IMPRESSIVE PRECLINICAL DATA WERE… Read more »

  • Fruit-basket-6401-638x300

    PUTTING ALL YOUR CANCER TYPES IN ONE BASKET

    TRADITIONAL CLINICAL TRIAL DESIGN IN ONCOLOGY OF GROUPING TOGETHER PATIENTS BASED ON THEIR CANCER TYPE HAS A HIGH ATTRITION RATE, WITH AN ESTIMATED 95% OF POTENTIAL ANTICANCER DRUGS FAILING DURING DEVELOPMENT. RESEARCHERS ARE CONSTANTLY WORKING ON WAYS TO OVERCOME THIS, AND ONE METHOD WHICH IS GAINING POPULARITY IS A “BASKET” STUDY, GROUPING TOGETHER PATIENTS BY… Read more »

  • digital-smoke-small-638x300

    REGULATORS BUTT IN ON E-CIGARETTES

    THE HEALTH RISKS OF SMOKING ARE WELL PUBLICIZED – AS WELL AS CAUSING AROUND 90% OF LUNG CANCERS AND MANY OTHER CANCER TYPES, SMOKING CAN ALSO TRIGGER LUNG, HEART, AND CIRCULATORY DISEASES. THE MOST RECENT SURVEY FROM THE US SHOWED THAT 43% OF SMOKERS HAD TRIED TO QUIT IN THE PAST YEAR, BUT WITHOUT MEDICATION… Read more »

  • iStock_000012157550Medium-638x300

    DYING FOR A SUNTAN?

    WITH SUMMER HERE AGAIN, MANY PEOPLE WILL BE JETTING OFF TO SUNNY LOCATIONS TO TOP UP THEIR TANS. PUBLIC HEALTH CAMPAIGNS HAVE HAD A LOT OF SUCCESS IN ENCOURAGING SUNBATHERS TO WEAR SUNSCREEN, TO CUT DOWN THEIR UV EXPOSURE AND PROTECT THEMSELVES FROM SKIN CANCER. HOWEVER, NEWLY PUBLISHED RESEARCH HAS SHOWN THAT SUNSCREEN ALONE CAN… Read more »

  • shot-in-arm-638x300

    A SHOT IN THE ARM FOR DIABETES RESEARCH

    CROWN BIOSCIENCE ATTENDED THE 74TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA) LAST MONTH IN SAN FRANCISCO. WHEN WE WEREN’T MANNING OUR BOOTH OR PRESENTING OUR SCIENTIFIC RESULTS (WITH ALL OUR POSTERS INCORPORATING THE LATEST LAYAR TECHNOLOGY) WE FOUND TIME TO REVIEW THE RESEARCH ON DISPLAY. ONE POSTER WHICH CAUGHT OUR ATTENTION PRESENTED DATA… Read more »

  • breakthrough-image-638x300

    FROM BENCH TO BEDSIDE FOR CANCER SIGNATURES

    EVERY RESEARCH SCIENTIST DREAMS OF PUBLISHING A NATURE OR SCIENCE PAPER, MAKING A GROUND BREAKING DISCOVERY IN THEIR FIELD AND IMPACTING ON FUTURE RESEARCH AROUND THE WORLD. ONE OF THE MAIN QUESTIONS IN ONCOLOGY IS “WHAT HAPPENS NEXT”? HOW IS HIGH IMPACT RESEARCH TURNED IN TO IMPROVED THERAPEUTIC OPTIONS? Within cancer research, major breakthroughs are… Read more »

  • iStock_000023334750Medium-638x300

    FDA BREATHES NEW LIFE INTO INHALED INSULIN

    THE FDA HAS APPROVED MANNKIND’S AFREZZA® AT THE THIRD TIME OF ASKING, MAKING IT THE FIRST INHALED INSULIN AVAILABLE FOR PEOPLE WITH DIABETES SINCE EXUBERA® IN 2006. AS CROWN BIOSCIENCE REVIEWED LAST MONTH, THE PATH TO FDA APPROVAL HAS NOT BEEN AN EASY ONE, WITH CONCERNS OVER EFFICACY, SAFETY, AND INHALER DESIGN. WHILE THIS APPROVAL… Read more »

  • right-home-638x300

    ORPHAN DRUGS FIND A HOME WITH THE FDA

    THE US ORPHAN DRUG ACT WAS DEVELOPED IN THE 1980S TO FACILITATE THE DEVELOPMENT AND COMMERCIALIZATION OF DRUGS TO TREAT RARE DISEASES, TERMED ORPHAN DRUGS. AT THAT TIME, FEW PEOPLE COULD HAVE PREDICTED THE MASSIVE STEP FORWARD THAT ONCOLOGY RESEARCH WOULD TAKE IN CHARACTERIZING THE MANY HETEROGENEOUS FORMS OF THE DISEASE, AND HOW THIS WOULD… Read more »

  • eye-638x300
  • lymphocytes-638x287

    ASPECTS OF ASCO

    CROWN BIOSCIENCE ATTENDED THE 50TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) IN CHICAGO THIS MONTH, THE THEME OF WHICH WAS SCIENCE AND SOCIETY. AS WELL AS MANNING A BOOTH INCORPORATING THE LATEST LAYAR TECHNOLOGY, CROWN BIOSCIENCE ALSO REVIEWED THE BEST OF THE CLINICAL ONCOLOGY RESEARCH ON DISPLAY. A HOT TOPIC AT… Read more »

  • ticking-638x300

    THE TICKING TIMEBOMB OF PREDIABETES

    AN ALARMING NEW STUDY HAS SHOWN THAT MORE THAN ONE IN THREE ADULTS IN ENGLAND IS ON THE VERGE OF DEVELOPING TYPE 2 DIABETES. THE NUMBER OF PREDIABETIC PEOPLE IN ENGLAND HAS TRIPLED IN ONLY 8 YEARS, AND WITHOUT INTERVENTION IS LIKELY TO RESULT IN A SHARP INCREASE IN THE NUMBER OF PEOPLE LIVING WITH,… Read more »

  • killer-eyes-638x253

    TAKING ON THE BIGGEST KILLER TAKES THE BEST

    IN 2012 THE WORLD HEALTH ORGANIZATION RANKED ISCHEMIC HEART DISEASE AS THE LEADING CAUSE OF DEATH WORLDWIDE. STROKE, DIABETES MELLITUS, AND HYPERTENSIVE HEART DISEASE ALSO MADE THE TOP TEN LIST OF KILLER DISEASES. THERE IS A GROWING NEED FOR NEW TREATMENTS IN CARDIOVASCULAR AND METABOLIC DISEASE (CVMD), YET TRANSLATIONAL RESEARCH IS OFTEN NOT AS FRUITFUL… Read more »

  • breathe-638x300
  • key-640-638x300

    CROWN BIOSCIENCE REVEALS THE KEY TO UNLOCKING YOUR PERFECT HUTRIAL™

    ONE OF THE MAIN GOALS OF TRANSLATIONAL RESEARCH FOR ONCOLOGY IS TO DISCOVER BIOMARKERS WHICH PREDICT CLINICAL EFFICACY. WITH THE WORLD’S LARGEST COLLECTION OF OVER 1,000 WELL-CHARACTERIZED PDX MODELS,HUPRIME®, AND HUBASE™ (A COMPREHENSIVE DATABASE OF GENOTYPIC, PHARMACOLOGICAL, AND PATIENT CLINICAL DATA ON HUPRIME MODELS), CROWN BIOSCIENCE IS ENABLING DRUG DISCOVERY ORGANIZATIONS TO PERFORM HUMAN SURROGATE… Read more »

  • next-gen-640-copy-638x300

    CANCER RESEARCH: THE NEXT GENERATION

    CROWN BIOSCIENCE ATTENDED THE 105TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH IN SAN DIEGO LAST MONTH, THE THEME OF WHICH WAS HARNESSING BREAKTHROUGHS – TARGETING CURES. AS WELL AS PRESENTING 8 SCIENTIFIC POSTERS ON RECENT CROWN BIOSCIENCE ADVANCES AND MANNING A BOOTH (BOTH OF WHICH INCORPORATED THE LATEST LAYAR TECHNOLOGY), CROWN BIOSCIENCE… Read more »

  • yesno-638x300

    ARE WE PICKING THE RIGHT BATTLES IN CERVICAL CANCER RESEARCH?

    SCREENING FOR CERVICAL CANCER IS VITALLY IMPORTANT AS IT IS ONE OF THE FEW CANCERS THAT CAN ACTUALLY BE PREVENTED BY PICKING UP EARLY CELLULAR CHANGES BEFORE THE DISEASE DEVELOPS. RECENT ADVANCES IN MOLECULAR TESTING HAD RESULTED IN THE MAINSTAY PAP SCREENING TEST BEING COMBINED WITH A TEST FOR HUMAN PAPILLOMAVIRUS (HPV) DNA, WHICH CAUSES… Read more »

  • GLY article photo640
  • Drowning in debt represented by a piggy bank sinking in blue water

    The cost of failure

    EVERYONE’S BEEN TRYING IT OVER THE LAST 10 YEARS OR MORE, BUT WHAT HAS BEEN THE TRUE IMPACT OF SIGNIFICANT CHANGES IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT, AND WHAT COULD BE THE FUTURE FOR DRUG DISCOVERY?

  • C 640

    What’s hot in Oncology today?

    Oncology, as with other areas of Drug Discovery, is a shifting landscape. As we come towards the end of 2013 we look forward to what some of the current trends and focus of Oncology may be in 2014.

  • stop

    Are you seeing resistance to your compound?

    In Oncology, drug resistance can limit the clinical benefit of a targeted agent. Understanding the molecular mechanisms of resistance is a key factor in discovering potential follow on drugs, combination therapies and treatment regimens for patients to manage their disease. But how do you model the multiplicity of options before entering the clinic?

  • spoonful640

    Why a spoonful doesn’t help the medicine go down.

    MANY OF THE FOODS WE EAT TODAY HAVE BECOME SIGNIFICANT AND CONTROVERSIAL SOCIAL AND HEALTH ISSUES. THE RISE OF THE INCIDENCE OF DIABETES AND DIABETES RELATED DISEASE IN NOT JUST THE WESTERN WORLD, BUT ALSO THE EMERGING ECONOMIES OF THE WORLD IS BECOMING A GLOBAL PHENOMENON WITH AN ASSOCIATED HIGHLY SIGNIFICANT HEALTHCARE BURDEN.

  • can't hear you!

    Echoes of ECCO

    17th European Cancer Congress, Amsterdam, 27 September to 1 October 2013 Reinforcing Multidisciplinarity. Will ECCO’s strapline for its forthcoming 17th European Cancer Congress mean that many struggle to understand the main theme of the event?